Please select the option that best describes you:

When, if ever, would you recommend risk reducing BSO in patients with moderate penetrance breast cancer germline mutations?  

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylactic oopherectomy or screening?

See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA pathogenic variants, and companion study (Kraft et al, 8/2021) evaluating the role of further characterization of polygenic risk score.



Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution
Sign in or Register to read more